Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan
- PMID: 34669154
- PMCID: PMC8527309
- DOI: 10.1007/s12185-021-03175-x
Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan
Abstract
Polymerase chain reaction (PCR) tests cannot always detect the SARS-CoV-2 virus, possibly due to differences in sensitivity between sample types. Under these circumstances, immunochromatography may serve as an alternative method to detect anti-SARS-CoV-2 IgG antibodies that indicate a history of infection. In our analysis of patients with severe COVID-19 infection, we found that 14 of 19 serum samples were positive for IgG antibodies, whereas 6 of 10 samples from patients with asymptomatic or mild cases were negative. Two patients with immune thrombocytopenia who were treated with prednisolone experienced aggressive COVID-19-related respiratory failure and eventually died. Patients not in remission and those who received steroid-based chemotherapy had a higher risk of death, and patients with lymphoid malignancies including lymphoma and myeloma died in larger numbers than those with myeloid malignancies. A stricter cohorting strategy based on repeat PCR tests or isolation to a private room should be adopted in routine care in hematology departments to prevent viral spread to the environment.
Keywords: Anti-SARS-CoV-2 IgG; COVID-19; Nosocomial infection; Survival.
© 2021. Japanese Society of Hematology.
Conflict of interest statement
The author declares that they have no conflicts of interest.
References
-
- Uchida T, Takagi Y, Mizuno A, et al. Retrospective analysis of nosocomial COVID-19: a comparison between patients with hematological disorders and other diseases. Rinshoketsueki. 2020;61:857–864. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous